CSL’s battered valuation offers asymmetric recovery potential if restructuring savings, Horizon 2 yields, and leadership renewal restore the plasma franchise.
Overview
CSL is a globally integrated biotechnology company operating CSL Behring, CSL Seqirus, and CSL Vifor. Behring generates approximately 68% of group revenue through plasma-derived and recombinant therapies, Seqirus contributes roughly 14% through influenza vaccines, and Vifor serves iron deficiency and nephrology markets. The company benefits from an extensive donor network, sophisticated fractionation capabilities, differentiated products such as home-administered Hizentra, and clinically inelastic demand. However, H1 FY2026 exposed severe execution and portfolio problems: revenue declined 4% at constant currency to USD 8.3 billion, underlying NPATA fell 7% to USD 1.9 billion, and statutory NPAT plunged 81% to USD 401 million after USD 1.1 billion of impairments and restructuring charges. **The recovery case depends on USD 500 million–USD 550 million of annual savings by FY2028 and successful Horizon 2 validation.** FY2026 revenue guidance was cut to approximately USD 15.2 billion and NPATA to USD 3.1 billion. At a compressed 14.5x P/E and an AUD 134.60 starting price, the report sees substantial five-year upside, but leadership, leverage, Vifor impairments, and FcRn competition remain material constraints.